Life Sciences revenues rose 3 percent year over year to $7.33 billion from $7.14 billion. Diagnostic revenues increased 2 percent to $9.79 billion from $9.58 billion, while Biotechnology revenues ...

For Q1 2025, Danaher said it expects core revenues will decline in the low-single digit percent range year over year. For full-year 2025, the company anticipates core revenues will increase ...

Life Sciences revenues rose 3 percent year over year to $7.33 billion from $7.14 billion. Diagnostic revenues increased 2 percent to $9.79 billion from $9.58 billion, while Biotechnology revenues ...

The test, which is intended for assessing cardiovascular risk, is the first lipoprotein (a), or Lp(a) test measured in nanomoles per liter to receive FDA clearance.

The €4.5 million ($4.2 million) effort is led by researchers from Sweden's Karolinska Institute and aims to deliver lateral flow tests and point-of-care devices.

The clinical chemistry test is intended to help diagnose heart failure using the N-terminal pro b-type natriuretic peptide biomarker.

Last week, readers were most interested in a story about Roche gaining FDA clearance and CLIA waiver for its STI point-of-care test.

The finalized local coverage determinations were set to go into effect on Feb. 23 but have been pushed back two months.

The molecular test is used to differentiate bacterial infections, viral infections, and noninfectious disease and to assess ...

NEW YORK – The US Department of Justice said last week that BioReference Health and Opko Health have agreed to pay $704,349 to resolve alleged violations of the False Claims Act. The government ...

The organization is leveraging its growing bank of whole-slide pathology images to create models that could form the backbone of cancer testing applications.

Roche plans to release the system in the US to run tests including vitamin D and steroid assays under CLIA before it possibly receives US Food and Drug Administration clearance.